ישראל - עברית - Ministry of Health

alexion pharma israel ltd - eculizumab - תרכיז להכנת תמיסה לאינפוזיה - eculizumab 10 mg/ml - eculizumab - eculizumab - soliris is indicated for the treatment of patients with: - paroxysmal nocturnal hemoglobinuria ( pnh ).- atypical hemolytic uremic syndrome (ahus).

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - neisseria meningitides group b strain nz98/254; neisseria meningitidis group b fhbp fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b nhba fusion protein - תרחיף להזרקה - neisseria meningitides group b strain nz98/254 25 mcg; neisseria meningitidis group b fhbp fusion protein 50 mcg; neisseria meningitidis group b nada protein 50 mcg; neisseria meningitidis group b nhba fusion protein 50 mcg - meningococcus b, outer membrane vesicle vaccine

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - meningococcus b, multicomponent vaccine; meningococcus b, multicomponent vaccine - תרחיף להזרקה - meningococcus b, multicomponent vaccine 60 mcg; meningococcus b, multicomponent vaccine 60 mcg - meningococcus b, multicomponent vaccine

ישראל - עברית - Ministry of Health

alexion pharma israel ltd - ravulizumab - תרכיז להכנת תמיסה לאינפוזיה - ravulizumab 10 mg/ml - ravulizumab

ישראל - עברית - Ministry of Health

alexion pharma israel ltd - ravulizumab - תרכיז להכנת תמיסה לאינפוזיה - ravulizumab 100 mg/ml - ravulizumab

ישראל - עברית - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - tocilizumab - תרכיז להכנת תמיסה לאינפוזיה - tocilizumab 20 mg/ml - tocilizumab - tocilizumab - actemra (tocilizumab) is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more dmards (disease modifying antirhematic drugs) or tnf antagonists or in whom dmards cannot be used. actemra can be used alone or in combination with methotrexate or other dmards.actemra® has been shown to reduce progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. actemra® is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

ישראל - עברית - Ministry of Health

takeda israel ltd - vedolizumab - אבקה להכנת תמיסה מרוכזת לעירוי - vedolizumab 300 mg/vial - vedolizumab

ישראל - עברית - Ministry of Health

takeda israel ltd - vedolizumab - תמיסה להזרקה - vedolizumab 158.8 mg / 1 ml - vedolizumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - tocilizumab - תמיסה להזרקה - tocilizumab 162 mg / 0.9 ml - tocilizumab